Data Sheet (Cat.No.T4352)

SB756050

Chemical Properties



CAS No. : 447410-57-3

Formula: C21H28N2O8S2

Molecular Weight: 500.59

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	SB756050 is a specific TGR5 agonist.
Targets(IC50)	GPCR19
In vitro	TGR5 is a potential target for the therapy of type 2 diabetes (T2D). Thus, SB756050 is used in phase 1clinical trials for the treatment of type 2 diabetes.
In vivo	SB756050 is well-tolerated with nonlinear pharmacokinetics. It shows dose-proportional increase in plasma exposure above 100 mg, and has no marked changes in exposure when co-administered with sitagliptin. SB756050 has highly variable pharmacodynamic effects both within between doses and dose groups, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 t sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different.

Solubility Information

Solubility	DMSO: 55 mg/mL (109.87 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9976 mL	9.9882 mL	19.9764 mL
5 mM	0.3995 mL	1.9976 mL	3.9953 mL
10 mM	0.1998 mL	0.9988 mL	1.9976 mL
50 mM	0.040 mL	0.1998 mL	0.3995 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Hodge RJ, et al. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481